Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nagase & Co. Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners. The prosecution is also split across 2 distinct art units, indicating that the company's active matters are being reviewed in different technical contexts within the patent office. This distribution shows that the company is pursuing at least two different technical paths simultaneously.
ZHANG SPIERING, DONGXIU is the busiest examiner for the company, with 1 busiest examiner pending action. Since there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for 1 matter. This balanced distribution across 2 distinct art units shows that no single examiner handles more than 1 action for the company. The involvement of 2 distinct examiners in the Biotechnology & Pharmaceuticals sector suggests independent prosecution timelines for each matter.
Practitioners should expect potentially different examination hurdles for each of the 2 pending office actions. The lack of overlap in examiners or art units means that the outcomes of these actions may be independent of one another. This structure requires the company to manage two separate administrative tracks within the Biotechnology & Pharmaceuticals area, each with its own set of prior art and procedural requirements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHANG SPIERING, DONGXIU | 1 | 41.2% | +65.2% |
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291346 | STABILIZATION OF MYCOSPORINE-LIKE AMINO ACIDS | ZHANG SPIERING, DONGXIU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18291346 | STABILIZATION OF MYCOSPORINE-LIKE AMINO ACIDS | ZHANG SPIERING, DONGXIU | — |
| 18548369 | ERGOTHIONEINE PRODUCTION METHOD | RAMIREZ, DELIA M | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18291346 | STABILIZATION OF MYCOSPORINE-LIKE AMINO ACIDS | ZHANG SPIERING, DONGXIU | 1616 | §103§112 | Non-Final OA | — | Pending | Jan 23, 2024 |
| 18548369 | ERGOTHIONEINE PRODUCTION METHOD | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | — | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNagase & Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dongxiu Zhang Spiering has the most, with 1 of Nagase & Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
